Page last updated: 2024-12-04

meglutol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Meglutol: An antilipemic agent which lowers cholesterol, triglycerides, serum beta-lipoproteins and phospholipids. It acts by interfering with the enzymatic steps involved in the conversion of acetate to hydroxymethylglutaryl coenzyme A as well as inhibiting the activity of HYDROXYMETHYLGLUTARYL COA REDUCTASES which is the rate limiting enzyme in the biosynthesis of cholesterol. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

3-hydroxy-3-methylglutaric acid : A dicarboxylic acid that is glutaric acid in which one of the two hydrogens at position 3 is substituted by a hydroxy group, while the other is substituted by a methyl group. It has been found to accumulate in urine of patients suffering from HMG-CoA lyase (3-hydroxy-3-methylglutaryl-CoA lyase, EC 4.1.3.4) deficiency. It occurs as a plant metabolite in Crotalaria dura. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

FloraRankFlora DefinitionFamilyFamily Definition
CrotalariagenusA plant genus of the family FABACEAE that contains crotalarin.[MeSH]FabaceaeThe large family of plants characterized by pods. Some are edible and some cause LATHYRISM or FAVISM and other forms of poisoning. Other species yield useful materials like gums from ACACIA and various LECTINS like PHYTOHEMAGGLUTININS from PHASEOLUS. Many of them harbor NITROGEN FIXATION bacteria on their roots. Many but not all species of beans belong to this family.[MeSH]

Cross-References

ID SourceID
PubMed CID1662
CHEMBL ID50444
CHEBI ID16831
SCHEMBL ID28443
MeSH IDM0023214

Synonyms (86)

Synonym
MLS001066390
smr000471861
CHEBI:16831 ,
meglutolum
3-hydroxy-3-methylglutaric acid
hmga
glutaric acid, beta-hydroxy methyl
nsc-361411
nsc361411
ACON1_000502
MEGXP0_001907
pentanedioic acid, 3-hydroxy-3-methyl-
einecs 207-971-1
brn 1769194
cb-337 ,
beta-hydroxy-beta-methylglutarate
meglutol [usan:inn]
nsc 361411
lipoglutaren
cb 337
medroglutaric acid
meglutolum [inn-latin]
glutaric acid, 3-hydroxy-3-methyl-
meglutol (usan/inn)
D04897
HMG ,
beta-hydroxy-beta-methylglutaric acid
dicrotalic acid
C03761
503-49-1
3-hydroxy-3-methylglutarate
3-hydorxy-3-methylglutaric acid
meglutol
3-hydroxy-3-methylpentanedioic acid
3-hydroxy-3-methyl-glutaric acid
DB04377
NCGC00169018-01
(s)-3-hydroxy-3-methylglutaric acid
(s)-meglutol
3-hydroxy-3-methylglutaric acid, >=95%
A90FC159-16ED-49CA-9A7F-D90B0A5B3EBC
AKOS000280741
CHEMBL50444 ,
BMSE000335
bdbm50160720
FT-0669836
H0436
HMS3264B09
pharmakon1600-01506183
nsc-760412
nsc760412
cla99kcd53 ,
4-03-00-01166 (beilstein handbook reference)
unii-cla99kcd53
meglutol [inn]
meglutol [usan]
meglutol [mi]
meglutol [mart.]
gtpl2960
CCG-213633
SCHEMBL28443
CS-4798
NPOAOTPXWNWTSH-UHFFFAOYSA-N
HY-B1189
AB00698060_04
DTXSID90198304
mfcd00002712
SR-01000763754-2
sr-01000763754
3-hydroxy-3-methylglutaric acid, purum, >=95.0% (gc)
AS-63885
3-hydroxy-3-methylglutaricacid
3-methyl-3-hydroxyglutarate
b-hydroxy-b-methylglutaric acid
dicrotalate
3-hydroxymethylglutarate
3-methyl-3-hydroxyglutaric acid
b-hydroxy-b-methylglutarate
Q524670
3-hydroxy-3-methylpentane-1
F17049
dicrotalic acid;3-hydroxy-3-methylglutaric acid
3-hydroxy-3-methylpentanedioic acid; dicrotalic acid; meglutol
A871595
3-hydroxy-3-methylpentane-1,5-dioic acid
3-hydroxy-3-methyl glutaric acid

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" There was no dose-response effect of sulpiride on serum levels of the monoamine metabolites or the amino acids."( Monoamine metabolites and amino acids in serum from schizophrenic patients before and during sulpiride treatment.
Alfredsson, G; Wiesel, FA, 1989
)
0.28
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (5)

RoleDescription
antimetaboliteA substance which is structurally similar to a metabolite but which competes with it or replaces it, and so prevents or reduces its normal utilization.
anticholesteremic drugA substance used to lower plasma cholesterol levels.
EC 1.1.1.34/EC 1.1.1.88 (hydroxymethylglutaryl-CoA reductase) inhibitorAny EC 1.1.1.* (oxidoreductase acting on donor CH-OH group, NAD(+) or NADP(+) acceptor) inhibitor that inhibits HMG-CoA reductases. Hydroxymethylglutaryl-CoA reductase inhibitors have been shown to lower directly cholesterol synthesis. The Enzyme Commission designation is EC 1.1.1.34 for the NADPH-dependent enzyme and EC 1.1.1.88 for an NADH-dependent enzyme.
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
plant metaboliteAny eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
dicarboxylic acidAny carboxylic acid containing two carboxy groups.
3-hydroxy carboxylic acidAny hydroxy carboxylic acid which contains a hydroxy group located beta- to the carboxylic acid group.
tertiary alcoholA tertiary alcohol is a compound in which a hydroxy group, -OH, is attached to a saturated carbon atom which has three other carbon atoms attached to it.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
3-hydroxy-3-methylglutaryl-coenzyme A reductaseHomo sapiens (human)IC50 (µMol)4.00000.00000.79498.9000AID241168
3-hydroxy-3-methylglutaryl-coenzyme A reductaseHomo sapiens (human)Ki0.02350.00090.00830.0235AID238540
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (10)

Processvia Protein(s)Taxonomy
cholesterol biosynthetic process3-hydroxy-3-methylglutaryl-coenzyme A reductaseHomo sapiens (human)
visual learning3-hydroxy-3-methylglutaryl-coenzyme A reductaseHomo sapiens (human)
coenzyme A metabolic process3-hydroxy-3-methylglutaryl-coenzyme A reductaseHomo sapiens (human)
negative regulation of protein catabolic process3-hydroxy-3-methylglutaryl-coenzyme A reductaseHomo sapiens (human)
negative regulation of protein secretion3-hydroxy-3-methylglutaryl-coenzyme A reductaseHomo sapiens (human)
long-term synaptic potentiation3-hydroxy-3-methylglutaryl-coenzyme A reductaseHomo sapiens (human)
regulation of ERK1 and ERK2 cascade3-hydroxy-3-methylglutaryl-coenzyme A reductaseHomo sapiens (human)
negative regulation of amyloid-beta clearance3-hydroxy-3-methylglutaryl-coenzyme A reductaseHomo sapiens (human)
isoprenoid biosynthetic process3-hydroxy-3-methylglutaryl-coenzyme A reductaseHomo sapiens (human)
sterol biosynthetic process3-hydroxy-3-methylglutaryl-coenzyme A reductaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (5)

Processvia Protein(s)Taxonomy
hydroxymethylglutaryl-CoA reductase (NADPH) activity3-hydroxy-3-methylglutaryl-coenzyme A reductaseHomo sapiens (human)
protein binding3-hydroxy-3-methylglutaryl-coenzyme A reductaseHomo sapiens (human)
GTPase regulator activity3-hydroxy-3-methylglutaryl-coenzyme A reductaseHomo sapiens (human)
NADPH binding3-hydroxy-3-methylglutaryl-coenzyme A reductaseHomo sapiens (human)
coenzyme A binding3-hydroxy-3-methylglutaryl-coenzyme A reductaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (3)

Processvia Protein(s)Taxonomy
peroxisomal membrane3-hydroxy-3-methylglutaryl-coenzyme A reductaseHomo sapiens (human)
endoplasmic reticulum3-hydroxy-3-methylglutaryl-coenzyme A reductaseHomo sapiens (human)
endoplasmic reticulum membrane3-hydroxy-3-methylglutaryl-coenzyme A reductaseHomo sapiens (human)
endoplasmic reticulum membrane3-hydroxy-3-methylglutaryl-coenzyme A reductaseHomo sapiens (human)
peroxisomal membrane3-hydroxy-3-methylglutaryl-coenzyme A reductaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (15)

Assay IDTitleYearJournalArticle
AID241168Inhibitory concentration against HMG-CoA reductase2005Bioorganic & medicinal chemistry letters, Feb-15, Volume: 15, Issue:4
Molecular docking of the highly hypolipidemic agent alpha-asarone with the catalytic portion of HMG-CoA reductase.
AID398685Acute toxicity in po dosed mouse1995Journal of natural products, Aug, Volume: 58, Issue:8
Identification of 3-hydroxy-3-methylglutaric acid (HMG) as a hypoglycemic principle of Spanish moss (Tillandsia usneoides).
AID398683Hypoglycemic activity in Swiss-Webster mouse assessed as change plasma glucose level at 250 mg/kg, ip after 4 hrs1995Journal of natural products, Aug, Volume: 58, Issue:8
Identification of 3-hydroxy-3-methylglutaric acid (HMG) as a hypoglycemic principle of Spanish moss (Tillandsia usneoides).
AID238540Inhibitory constant against HMG-CoA reductase2005Bioorganic & medicinal chemistry letters, Feb-15, Volume: 15, Issue:4
Molecular docking of the highly hypolipidemic agent alpha-asarone with the catalytic portion of HMG-CoA reductase.
AID81008In vitro inhibition of rat liver HMG-CoA reductase at concentration of 10e-3 M1985Journal of medicinal chemistry, May, Volume: 28, Issue:5
3-Alkyl-3-hydroxyglutaric acids: a new class of hypocholesterolemic HMG CoA reductase inhibitors. 1.
AID182104Percent inhibition of [14C]acetate incorporation into long-chain fatty acids, after incubation with rat liver slices, at a concentration of 0.005 M1983Journal of medicinal chemistry, Dec, Volume: 26, Issue:12
Synthesis of 3-hydroxy-3-cyclohexylbutyric acid derivatives. 1. Cyclic homologues of 3-hydroxy-3-methylglutaric acid.
AID398689Toxicity in patient with familial hypercholesterolemia at 750 to 2250 mg/day in 3 divided doses for 8 weeks1995Journal of natural products, Aug, Volume: 58, Issue:8
Identification of 3-hydroxy-3-methylglutaric acid (HMG) as a hypoglycemic principle of Spanish moss (Tillandsia usneoides).
AID398687Antihypercholesterolemic activity in patient with familial hypercholesterolemia assessed as decrease in plasma cholesterol at 2250 mg/day in 3 divided doses for 8 weeks1995Journal of natural products, Aug, Volume: 58, Issue:8
Identification of 3-hydroxy-3-methylglutaric acid (HMG) as a hypoglycemic principle of Spanish moss (Tillandsia usneoides).
AID182096Percent inhibition of [14C]acetate incorporation into CO2, after incubation with rat liver slices at a concentration of 0.005 M1983Journal of medicinal chemistry, Dec, Volume: 26, Issue:12
Synthesis of 3-hydroxy-3-cyclohexylbutyric acid derivatives. 1. Cyclic homologues of 3-hydroxy-3-methylglutaric acid.
AID398688Antihypercholesterolemic activity in patient with familial hypercholesterolemia assessed as decrease in plasma cholesterol at 3000 mg/day in 3 divided doses for 8 weeks1995Journal of natural products, Aug, Volume: 58, Issue:8
Identification of 3-hydroxy-3-methylglutaric acid (HMG) as a hypoglycemic principle of Spanish moss (Tillandsia usneoides).
AID182100Percent inhibition of [14C]acetate incorporation into cholesterol, after incubation with rat liver slices, at a concentration of 0.005 M1983Journal of medicinal chemistry, Dec, Volume: 26, Issue:12
Synthesis of 3-hydroxy-3-cyclohexylbutyric acid derivatives. 1. Cyclic homologues of 3-hydroxy-3-methylglutaric acid.
AID398684Toxicity in brine shrimp1995Journal of natural products, Aug, Volume: 58, Issue:8
Identification of 3-hydroxy-3-methylglutaric acid (HMG) as a hypoglycemic principle of Spanish moss (Tillandsia usneoides).
AID398691Hypoglycemic activity in Swiss-Webster mouse assessed as change plasma glucose level at 125 mg/kg, ip after 4 hrs1995Journal of natural products, Aug, Volume: 58, Issue:8
Identification of 3-hydroxy-3-methylglutaric acid (HMG) as a hypoglycemic principle of Spanish moss (Tillandsia usneoides).
AID398690Hypoglycemic activity in Swiss-Webster mouse assessed as change plasma glucose level at 62.5 mg/kg, ip after 4 hrs1995Journal of natural products, Aug, Volume: 58, Issue:8
Identification of 3-hydroxy-3-methylglutaric acid (HMG) as a hypoglycemic principle of Spanish moss (Tillandsia usneoides).
AID398686Acute toxicity in ip dosed mouse1995Journal of natural products, Aug, Volume: 58, Issue:8
Identification of 3-hydroxy-3-methylglutaric acid (HMG) as a hypoglycemic principle of Spanish moss (Tillandsia usneoides).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (135)

TimeframeStudies, This Drug (%)All Drugs %
pre-199054 (40.00)18.7374
1990's33 (24.44)18.2507
2000's20 (14.81)29.6817
2010's23 (17.04)24.3611
2020's5 (3.70)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 25.25

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index25.25 (24.57)
Research Supply Index4.98 (2.92)
Research Growth Index4.45 (4.65)
Search Engine Demand Index31.58 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (25.25)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (1.40%)5.53%
Reviews7 (4.90%)6.00%
Case Studies46 (32.17%)4.05%
Observational1 (0.70%)0.25%
Other87 (60.84%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]